Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Malignant mesothelioma in situ: morphologic features and clinical outcome.

Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, Chang N, De Perrot M, Dacic S.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0347-0. [Epub ahead of print]

PMID:
31375770
2.

In Reply to "Malignant Mesothelioma and Its Nonasbestos Causes".

Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL.

Arch Pathol Lab Med. 2019 Aug;143(8):911-914. doi: 10.5858/arpa.2019-0060-LE. No abstract available.

PMID:
31339754
3.

Reproducibility of visual estimation of lung adenocarcinoma subtype proportions.

Wright J, Churg A, Kitaichi M, Yang HM, Hyde D, Yi E.

Mod Pathol. 2019 Jun 23. doi: 10.1038/s41379-019-0308-7. [Epub ahead of print]

PMID:
31231130
4.

MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.

Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, Galateau-Salle F, Hiroshima K, Krausz T, Le Stang N, McGregor S, Nabeshima K, Husain AN.

Mod Pathol. 2019 Jun 23. doi: 10.1038/s41379-019-0310-0. [Epub ahead of print]

PMID:
31231127
5.

Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists.

Monroig-Bosque PDC, Morales-Rosado JA, Roden AC, Churg A, Barrios R, Cagle P, Ge Y, Allen TC, Smith ML, Larsen BT, Sholl LM, Beasley MB, Borczuk A, Raparia K, Ayala A, Tazelaar HD, Miller R, Kalhor N, Moran CA, Ro JY.

Ann Diagn Pathol. 2019 Apr 24;41:43-50. doi: 10.1016/j.anndiagpath.2019.04.008. [Epub ahead of print]

PMID:
31132651
6.

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen T, Daugaard M, Sahinalp SC, Hach F, Le Bihan S, Gleave ME, Wang Y, Churg A, Collins CC.

Genome Med. 2019 Feb 18;11(1):8. doi: 10.1186/s13073-019-0620-3.

7.

Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Chapel DB, Churg A, Santoni-Rugiu E, Tsujimura T, Hiroshima K, Husain AN.

Lung Cancer. 2019 Jan;127:69-75. doi: 10.1016/j.lungcan.2018.11.032. Epub 2018 Nov 26. Review.

PMID:
30642555
8.

Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease.

Grewal JS, Morisset J, Fisher JH, Churg AM, Bilawich AM, Ellis J, English JC, Hague CJ, Khalil N, Leipsic J, Mayo J, Muller NL, Murphy D, Wright JL, Ryerson CJ.

Ann Am Thorac Soc. 2019 Apr;16(4):455-462. doi: 10.1513/AnnalsATS.201811-794OC.

PMID:
30608873
9.

MUC4 Staining in Sarcomatoid Carcinomas.

Berg KB, Ionescu D, Churg AM.

Mod Pathol. 2019 Jan;32(1):157. doi: 10.1038/s41379-018-0022-x. Epub 2018 Dec 19. No abstract available.

PMID:
30568230
10.

Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report.

Ong S, Levy RD, Yee J, Partovi N, Churg A, Roméo P, Chalaoui J, Nador R, Wright A, Manganas H, Ryerson CJ.

BMC Pulm Med. 2018 Oct 16;18(1):162. doi: 10.1186/s12890-018-0727-0.

11.

Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.

Churg A, Nabeshima K, Ali G, Bruno R, Fernandez-Cuesta L, Galateau-Salle F.

Lung Cancer. 2018 Oct;124:95-101. doi: 10.1016/j.lungcan.2018.07.041. Epub 2018 Jul 30.

PMID:
30268487
12.

Histopathologic findings in lung biopsies from patients with primary biliary cholangitis.

Lee HE, Churg A, Ryu JH, Bilawich AM, Larsen BT, Tazelaar HD, Yi ES.

Hum Pathol. 2018 Dec;82:177-186. doi: 10.1016/j.humpath.2018.07.021. Epub 2018 Jul 29.

PMID:
30067952
13.
14.

Biopsy-proven recurrent, acute, familial hypersensitivity pneumonitis: A case report and literature review.

Winstone T, Hague CJ, Churg A, Wright JL, Schellenberg R, Ryerson C.

Respir Med Case Rep. 2018 May 17;24:173-175. doi: 10.1016/j.rmcr.2018.05.007. eCollection 2018.

15.

Does Compromised Immune Exclusion Drive Inflammatory Processes in Chronic Obstructive Pulmonary Disease?

Stampfli MR, Churg AM.

Am J Respir Cell Mol Biol. 2018 Jun;58(6):671-672. doi: 10.1165/rcmb.2018-0039ED. No abstract available.

PMID:
29856258
16.

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

Chiu K, Lee L, Cheung S, Churg AM.

Mod Pathol. 2018 Sep;31(9):1400-1403. doi: 10.1038/s41379-018-0066-y. Epub 2018 May 21.

PMID:
29785020
17.

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N.

J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30.

18.

Malignant Mesothelioma and Its Non-Asbestos Causes.

Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL.

Arch Pathol Lab Med. 2018 Jun;142(6):753-760. doi: 10.5858/arpa.2017-0365-RA. Epub 2018 Feb 26. Review.

PMID:
29480760
19.

Malignant mesothelioma in situ.

Churg A, Hwang H, Tan L, Qing G, Taher A, Tong A, Bilawich AM, Dacic S.

Histopathology. 2018 May;72(6):1033-1038. doi: 10.1111/his.13468. Epub 2018 Feb 26.

PMID:
29350783
20.

ERS/ATS workshop report on respiratory health effects of household air pollution.

Sood A, Assad NA, Barnes PJ, Churg A, Gordon SB, Harrod KS, Irshad H, Kurmi OP, Martin WJ 2nd, Meek P, Mortimer K, Noonan CW, Perez-Padilla R, Smith KR, Tesfaigzi Y, Ward T, Balmes J.

Eur Respir J. 2018 Jan 4;51(1). pii: 1700698. doi: 10.1183/13993003.00698-2017. Print 2018 Jan.

21.

Cicatricial organising pneumonia mimicking a fibrosing interstitial pneumonia.

Churg A, Wright JL, Bilawich A.

Histopathology. 2018 Apr;72(5):846-854. doi: 10.1111/his.13443. Epub 2018 Jan 29.

PMID:
29193209
22.

The Many Faces of Hypersensitivity Pneumonitis.

Churg A, Ryerson CJ.

Chest. 2017 Sep;152(3):458-460. doi: 10.1016/j.chest.2017.03.024. No abstract available.

PMID:
28889874
23.

Organizing Pneumonia in an Adult With Chronic Recurrent Noninfectious Osteomyelitis: A Case Report and Literature Review.

Winstone TA, Levy RD, Shojania K, Murphy D, Churg A, Ryerson C.

Chest. 2017 Aug;152(2):e21-e24. doi: 10.1016/j.chest.2017.04.172. Review.

PMID:
28797395
24.

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Marchevsky AM, LeStang N, Hiroshima K, Pelosi G, Attanoos R, Churg A, Chirieac L, Dacic S, Husain A, Khoor A, Klebe S, Lantuejoul S, Roggli V, Vignaud JM, Weynard B, Sauter J, Henderson D, Nabeshima K, Galateau-Salle F.

Hum Pathol. 2017 Sep;67:160-168. doi: 10.1016/j.humpath.2017.07.015. Epub 2017 Aug 4. Review.

PMID:
28782639
25.

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR.

Arch Pathol Lab Med. 2018 Jan;142(1):89-108. doi: 10.5858/arpa.2017-0124-RA. Epub 2017 Jul 7.

PMID:
28686500
26.

Pathologic Separation of Chronic Hypersensitivity Pneumonitis From Fibrotic Connective Tissue Disease-associated Interstitial Lung Disease.

Churg A, Wright JL, Ryerson CJ.

Am J Surg Pathol. 2017 Oct;41(10):1403-1409. doi: 10.1097/PAS.0000000000000885.

PMID:
28614213
27.

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.

Berg KB, Churg A.

Am J Surg Pathol. 2017 Sep;41(9):1221-1225. doi: 10.1097/PAS.0000000000000825.

PMID:
28614203
28.

Pathology of Chronic Hypersensitivity Pneumonitis What Is It? What Are the Diagnostic Criteria? Why Do We Care?

Churg A, Bilawich A, Wright JL.

Arch Pathol Lab Med. 2018 Jan;142(1):109-119. doi: 10.5858/arpa.2017-0173-RA. Epub 2017 May 24. Review.

PMID:
28537805
29.

Pleural amyloidosis imitating pleural malignancy.

Coolbear F, Bilawich AM, Tongson J, Adamo J, Churg A.

Respir Med Case Rep. 2017 Mar 6;20:195-197. doi: 10.1016/j.rmcr.2017.03.004. eCollection 2017.

30.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L.

Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Review.

31.

Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.

Owen D, Sheffield BS, Ionescu D, Churg A.

Hum Pathol. 2017 Feb;60:82-85. doi: 10.1016/j.humpath.2016.10.005. Epub 2016 Oct 28.

PMID:
27984124
32.

Role of Immunohistochemistry in the Diagnosis of Solitary Fibrous Tumor, a Review.

Geramizadeh B, Marzban M, Churg A.

Iran J Pathol. 2016 Summer;11(3):195-203. Review.

33.

Sex-Related Differences in Pulmonary Function following 6 Months of Cigarette Exposure: Implications for Sexual Dimorphism in Mild COPD.

Tam A, Bates JH, Churg A, Wright JL, Man SF, Sin DD.

PLoS One. 2016 Oct 27;11(10):e0164835. doi: 10.1371/journal.pone.0164835. eCollection 2016.

34.

Reply: Coal Mine Dust Lung Disease That Persists below the Surface of Surveillance: Down Under.

Cohen RA, Rose C, Petsonk EL, Abraham JL, Green FH, Churg A.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):773-4. doi: 10.1164/rccm.201604-0779LE. No abstract available.

PMID:
27628082
35.

Pathology of Asbestosis: An Update of the Diagnostic Criteria Response to a Critique.

Roggli V, Gibbs AR, Attanoos R, Churg A, Popper H, Corrin B, Franks T, Galateau-Salle F, Galvin J, Hasleton P, Honma K.

Arch Pathol Lab Med. 2016 Sep;140(9):950-2. doi: 10.5858/arpa.2015-0503-SA. No abstract available.

PMID:
27575267
36.

Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations.

Sheffield BS, Lorette J, Shen Y, Marra MA, Churg A.

Arch Pathol Lab Med. 2016 May;140(5):391. doi: 10.5858/arpa.2015-0508-LE. No abstract available.

PMID:
27128293
37.

Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Churg A, Attanoos R, Borczuk AC, Chirieac LR, Galateau-Sallé F, Gibbs A, Henderson D, Roggli V, Rusch V, Judge MJ, Srigley JR.

Arch Pathol Lab Med. 2016 Oct;140(10):1104-10. doi: 10.5858/arpa.2016-0073-OA. Epub 2016 Mar 31.

38.

BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.

Hwang HC, Pyott S, Rodriguez S, Cindric A, Carr A, Michelsen C, Thompson K, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2016 May;40(5):714-8. doi: 10.1097/PAS.0000000000000616.

PMID:
26900815
39.

Confluent fibrosis and fibroblast foci in fibrotic non-specific interstitial pneumonia.

Churg A, Bilawich A.

Histopathology. 2016 Jul;69(1):128-35. doi: 10.1111/his.12950. Epub 2016 Mar 31.

PMID:
26864142
40.

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.

Galateau-Salle F, Churg A, Roggli V, Travis WD; World Health Organization Committee for Tumors of the Pleura.

J Thorac Oncol. 2016 Feb;11(2):142-54. doi: 10.1016/j.jtho.2015.11.005. Review.

41.

Reply: Bronchiolitis by Any Other Name: Describing Bronchiolar Disorders from Inhalational Exposures.

Churg A, Ryerson CJ.

Ann Am Thorac Soc. 2016 Jan;13(1):144. doi: 10.1513/AnnalsATS.201511-752LE. No abstract available.

PMID:
26730875
42.

Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease.

Tam A, Churg A, Wright JL, Zhou S, Kirby M, Coxson HO, Lam S, Man SF, Sin DD.

Am J Respir Crit Care Med. 2016 Apr 15;193(8):825-34. doi: 10.1164/rccm.201503-0487OC.

PMID:
26599602
43.

Lung Pathology in U.S. Coal Workers with Rapidly Progressive Pneumoconiosis Implicates Silica and Silicates.

Cohen RA, Petsonk EL, Rose C, Young B, Regier M, Najmuddin A, Abraham JL, Churg A, Green FH.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):673-80. doi: 10.1164/rccm.201505-1014OC.

44.

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.

Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2016 Jan;40(1):120-6. doi: 10.1097/PAS.0000000000000529.

PMID:
26448191
45.

Unclassifiable interstitial lung disease: an unresolved diagnostic dilemma.

Leung SC, Churg AM, Leipsic JA, Levy RD, Wilcox PG, Ryerson CJ.

Respirol Case Rep. 2015 Sep;3(3):85-8. doi: 10.1002/rcr2.112. Epub 2015 Jun 9.

46.

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

Churg A, Sheffield BS, Galateau-Salle F.

Arch Pathol Lab Med. 2016 Apr;140(4):318-21. doi: 10.5858/arpa.2015-0240-SA. Epub 2015 Aug 19.

PMID:
26288396
47.

Fibrosing Bronchiolitis Evolving from Infectious or Inhalational Acute Bronchiolitis. A Reversible Lesion.

Ryerson CJ, Olsen SR, Carlsten C, Donagh C, Bilawich AM, Field SK, Churg A.

Ann Am Thorac Soc. 2015 Sep;12(9):1323-7. doi: 10.1513/AnnalsATS.201504-234BC.

PMID:
26153612
48.

Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.

Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, Ch'ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J, Marra MA.

PLoS One. 2015 Mar 23;10(3):e0119689. doi: 10.1371/journal.pone.0119689. eCollection 2015.

49.

Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.

Zachara-Szczakowski S, Verdun T, Churg A.

Hum Pathol. 2015 May;46(5):776-82. doi: 10.1016/j.humpath.2015.02.001. Epub 2015 Feb 19.

PMID:
25776027
50.

BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.

Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2015 Jul;39(7):977-82. doi: 10.1097/PAS.0000000000000394.

PMID:
25634745

Supplemental Content

Support Center